trending Market Intelligence /marketintelligence/en/news-insights/trending/gfoxmdjr2wlltls130fbyq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Biogen secures US FDA approval for spinal muscular atrophy treatment

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Biogen secures US FDA approval for spinal muscular atrophy treatment

Biogen Inc. said it received U.S. FDA approval for SPINRAZA, a treatment for spinal muscular atrophy.

The drug was approved following positive results from multiple clinical studies in more than 170 patients. In a controlled clinical study, those treated with the drug showed clinically meaningful improvements in their motor functions. Also, a greater percentage of patients on the drug survived compared to untreated patients.

Biogen plans to make the drug available for shipment in the U.S. to healthcare providers in about a week.